EUVIMEDEUVIMED entdecken
Open Access

Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy

Maria Gioulvanidou, Selenay Sarklioglu, Xinlei Chen, Irina V Lebedeva, Yeliz Inalman, Mary Ann Pohl, Lloyd Bourne, David Andrew, Ivo C Lorenz iD, Katie M Stiles, Odelya E Pagovich, Neil R Hackett und 3 weitere

Human Gene Therapy · 2025

DOI: 10.1089/hum.2024.165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Maria Gioulvanidou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Eosinophils, Genetic Vectors, Antibodies, Monoclonal. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hypereosinophilia, defined as persistent elevated blood levels of eosinophils ≥1,500/μL, is associated with tissue infiltration of eosinophils and consequent organ damage by eosinophil release of toxic mediators. The current therapies for chronic hypereosinophilia have limited success, require repetitive administration, and are associated with a variety of adverse effects. As a novel approach to treat chronic hypereosinophilia, we hypothesized that adeno-associated virus (AAV)-mediated delivery of an anti-human eosinophil antibody would provide one-time therapy that would mediate persistent suppression of blood eosinophil levels. To assess this hypothesis, we first generated a human monoclonal antibody (mAb) directed against Siglec8, a sialic-acid binding immunoglobulin-like lectin, expressed at high levels on the cell surface of human eosinophils. Transgenic mice with a human immunoglobulin repertoire were immunized with human Siglec8 protein or DNA encoding human Siglec8. Based on target binding assessments, the 08C07 mAb was chosen for further study. The human variable regions of 08C07 were joined to the human Ig constant region, creating H08C07 (hAntiEos), a fully human anti-human eosinophil mAb. Using the gene sequence of hAntiEos, we created AAVrh.10hAntiEos, an AAVrh.10-based vector expressing the heavy and light chains of H08C07. Intravenous administration of AAVrh.10hAntiEos (10 11 genome copies or gc) to C57Bl/6 mice resulted in persistent elevated serum levels of hAntiEos. In vivo gene therapy generated hAntiEos bound to recombinant human Siglec8 protein in a dose-dependent manner and to human eosinophils, mediated apoptosis of human eosinophils, and antibody-dependent cellular cytotoxicity activity against human eosinophils. Consistent with these data, administration of AAVrh.10hAntiEos to human CD34 + transplanted NSG-SGM3 immunodeficient mice suppressed levels of human eosinophils in vivo . AAVrh.10hAntiEos holds the potential to offer therapeutic benefit to patients with chronic hypereosinophilia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyEosinophilsGenetic VectorsAntibodies, MonoclonalHypereosinophilic SyndromeAntigens, CDAnimalsHumansDependovirusMiceMice, TransgenicLectinsAntigens, Differentiation, B-Lymphocyte

Stichwörter der Autor:innen

adeno-associated viruseosinophiliagene therapy

Substanzen

Antibodies, MonoclonalSIGLEC8 protein, humanLectinsAntigens, CDAntigens, Differentiation, B-Lymphocyte

Autor:innen und Institutionen

  • Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA.
  • Sanders Tri-Institutional Therapeutics Discovery Institute, New York, New York, USA.

ORCID-Profile: Ivo C Lorenz, Stephen M Kaminsky, Ronald G Crystal

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Gioulvanidou, M., Sarklioglu, S., Chen, X., Lebedeva, I. V., Inalman, Y., Pohl, M. A., Bourne, L., Andrew, D., Lorenz, I. C., Stiles, K. M., Pagovich, O. E., Hackett, N. R., Kaminsky, S. M., de Mulder Rougvie, M., & Crystal, R. G. (2025). Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy. Human Gene Therapy. https://doi.org/10.1089/hum.2024.165

Vancouver

Gioulvanidou M, Sarklioglu S, Chen X, Lebedeva IV, Inalman Y, Pohl MA, et al. Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy. Human Gene Therapy. 2025. doi:10.1089/hum.2024.165

BibTeX
@article{Gioulvanidou2025,
  author = {Gioulvanidou, Maria and Sarklioglu, Selenay and Chen, Xinlei and Lebedeva, Irina V and Inalman, Yeliz and Pohl, Mary Ann and Bourne, Lloyd and Andrew, David and Lorenz, Ivo C and Stiles, Katie M and Pagovich, Odelya E and Hackett, Neil R and Kaminsky, Stephen M and de Mulder Rougvie, Miguel and Crystal, Ronald G},
  title = {Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy},
  journal = {Human Gene Therapy},
  year = {2025},
  doi = {10.1089/hum.2024.165}
}
Kostenlos starten →